U031 Prurigo Nodularis
DESCRIPTION
This session will provide a cutting-edge discussion about our current understanding of prurigo nodularis (PN) for clinicians. We will present various clinical presentations of prurigo nodularis, discuss novel therapeutics, and highlight the patient journey. This session is directed towards dermatologists and other health care providers who treat adults with prurigo nodularis.
LEARNING OBJECTIVES
Recognize the various clinical morphologies and disease presentations of prurigo nodularis
Differentiate therapeutic options for prurigo nodularis
Describe the patient journey in prurigo nodularis
SCHEDULE
7:30 AM
Introduction
Shawn Kwatra, MD, FAAD
7:40 AM
Interactive Clinical Cases I
Sarina Elmariah, MD, FAAD
8:00 AM
Interactive Clinical Cases II
Shawn Kwatra, MD, FAAD
8:00 AM
Discussion
8:20 AM
Q&A
DIRECTOR
Shawn Kwatra, MD, FAAD
SPEAKER
Sarina Elmariah, MD, FAAD
DISCLOSURES
Sarina Elmariah, MD, FAAD
Eli Lilly – Other(Honoraria); Galderma Laboratories, LP – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Shawn Kwatra, MD, FAAD
AbbVie – Consultant(Honoraria); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); Castle Biosciences, Inc – Consultant(Honoraria); Galderma – Investigator(Grants/Research Funding); Galderma USA – Consultant(Honoraria); Incyte Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Johnson and Johnson – Advisory Board(Honoraria); Leo Pharma Inc – Advisory Board(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding);